
Vidacare of Shavano Park, Texas is touting results of three studies just presented at the annual meeting of the American Society of Hematology in Orlando, Florida that studied the benefits of using the company’s OnControl bone biopsy and aspiration device.
The long and short of these studies is that the device is faster to use, less painful on the patient, and results in a significantly larger specimen size (see side image) than traditional manual corking.
Here’s a summary of results from Study 1:
124% faster procedure time for OnControl when compared to Manual Significantly lower needle insertion pain (2.6 vs 4.1 on a VAS scale of 0-10) Significantly larger core biopsy specimen with mean volume for OnControl at 36.8mm compared to 15.3mm for Manual Significantly larger core biopsy specimen with mean usable area for OnControl at 25.4mm compared to 11.9mm for Manual.
Study 2:
100% core biopsy sample core capture rate for OnControl compared to 67% for manual 83% faster procedure time for OnControl when compared to manual Significantly lower overall pain (20.9 vs 33.3 on a VAS scale of 0-100) Significantly larger core biopsy specimens with a mean volume for OnControl of 49.12mm compared to 10.76mm for manual.
Study 3
109% faster procedure time for OnControl compared to Manual Significantly more OnControl patients were pain free 24 hours after the biopsy procedure; 67%
compared to 33% for Manual patientsSignificantly larger core biopsy specimens with a mean volume for OnControl of 36.8mm compared
to 20.4mm for Manual.
More details in the press release: Studies Show New Bone Marrow Biopsy Technology Delivers Superior Samples, Less Pain when Compared to Manual Devices…
Product page: OnControl…







PEPID mobile platform is now available on the Apple iPad and can run the entire suite of PEPID clinical reference products. Apparently the beta testers recruited last October “widely praised and accepted’ the app. This makes PEPID now available on all iOS devices as well as Android, BlackBerry, Windows Mobile and Palm.



East Carolina University, Yale University, and Humacyte have shown some promising results with tissue-engineered vascular grafts (TEVGs). TEVGs are bioengineered veins that can be used for coronary artery bypass graft surgery and vascular access for hemodialysis. The veins, with a diameter of 3 to 6 mm, were generated in a bioreactor using human and canine smooth muscle cells, decellularized, and stored up to 12 months in refrigerated conditions. After that the veins were implanted in nine adult male baboons and five mongrel dogs. They showed excellent blood flow and resistance to dilatation, calcification and intimal hyperplasia, meaning less chance of occlusion. With this technique, patients who do not have suitable veins of their own could be helped with donor material. One donor could produce grafts for multiple patients. Being tested on animals, this is still in early development, but the results are hopeful. Results were published in the journal Science Translational Medicine.
Researchers from Connecticut College have been experimenting with luciferase enzyme, the stuff that makes the abdomen of fireflies glow, as a potential agent for generation of near-infrared (nIR) light. This was accomplished by labeling a luciferase variant with nIR fluorescent dyes. The method was used to detect small amounts of blood factor Xa, a coagulation factor inhibited by antithrombin III during heparin therapy, hence the idea this this technology might be used to monitor coagulation.




